Related Experiment Video

Updated: Aug 19, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Amyloid inhibitors and Alzheimer's disease

Weiming Xia1

  • 1Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, 77 Ave Louis Pasteur, Boston, MA 02115, USA. wxia@rics.bwh.harvard.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 11, 2003
PubMed

Insights

Alzheimer's disease (AD) features amyloid beta plaques. Current research targets reducing A beta production or toxicity, with repurposed drugs entering trials needing further investigation into their mechanisms and relevance to A beta toxicity.

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is characterized by neuritic plaques of amyloid beta-protein (A beta).
  • A beta aggregation and deposition are central to AD pathogenesis.
  • Current therapeutic strategies focus on modulating A beta production, aggregation, or toxicity.

Purpose of the Study:

  • To review current preclinical drug development strategies for Alzheimer's disease.
  • To emphasize the need for thorough investigation of molecular targets for repurposed drugs in AD clinical trials.
  • To highlight the importance of understanding A beta-related pathways for novel therapeutic interventions.

Main Methods:

  • Review of current preclinical research and clinical trial approaches for Alzheimer's disease.
  • Analysis of therapeutic strategies targeting amyloid beta production and toxicity.
  • Discussion on the relevance of molecular targets for repurposed drugs in AD.

Main Results:

  • Preclinical drug development primarily focuses on inhibiting beta- or gamma-secretase to reduce A beta production.
  • Strategies also aim to prevent A beta protofibril/fibril formation and mitigate neuritic plaque toxicity.
  • Numerous drugs for other conditions are entering AD clinical trials, necessitating a clear understanding of their mechanisms.

Conclusions:

  • Understanding the molecular targets and A beta relevance of repurposed drugs is crucial for effective AD therapy.
  • Further research into A beta-related pathways will facilitate the development of novel and targeted Alzheimer's disease interventions.
  • Comprehensive knowledge of drug mechanisms is essential for advancing Alzheimer's disease treatment.

More Related Videos

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...